PMID- 34376135
OWN - NLM
STAT- MEDLINE
DCOM- 20220517
LR  - 20220606
IS  - 1875-6417 (Electronic)
IS  - 1573-3998 (Linking)
VI  - 18
IP  - 3
DP  - 2022
TI  - Role of Glycogen Synthase Kinase-3 in the Etiology of Type 2 Diabetes Mellitus: A 
      Review.
PG  - e300721195147
LID - 10.2174/1573399817666210730094225 [doi]
AB  - The risk of type 2 diabetes mellitus (T2DM) is increasing abundantly due to 
      lifestyle-related obesity and associated cardiovascular problems. Presently, 
      Glycogen synthase kinase-3 (GSK-3) has gained considerable attention from 
      biomedical scientists to treat diabetes. Phosphorylation of GSK-3 permits a 
      number of cellular activities like regulation of cell signaling, cellular 
      metabolism, cell proliferation and cellular transport. Inhibiting GSK-3 activity 
      by pharmacological intervention has become an important strategy for the 
      management of T2DM. This review focuses on the schematic representation of 
      fundamental GSK-3 enzymology and encompasses the GSK-3 inhibitors as a future 
      therapeutic lead target for the management of T2DM that may significantly 
      regulate insulin sensitivity to insulin receptor, glycogen synthesis and glucose 
      metabolism. The various signaling mechanisms of inhibiting the GSK-3 by 
      describing insulin signaling through Insulin Receptor Substrate (IRS-1), 
      Phosphatidylinositol-3 Kinase (PI3K) and Protein Kinase B (PKB/ AKT) pathways 
      that may hopefully facilitate the pharmacologist to design for antidiabetic drug 
      evaluation model in near future have also been highlighted.
CI  - Copyright(c) Bentham Science Publishers; For any queries, please email at 
      epub@benthamscience.net.
FAU - Bala, Asis
AU  - Bala A
AD  - Department of Pharmacology and Toxicology, National Institute of Pharmaceutical 
      Education and Research, EPIP Campus, Hajipur, Bihar 844102, India.
AD  - Division of Pharmacology and Toxicology, Guru Nanak Institute of Pharmaceutical 
      Science and Technology, 157/F, Nilgunj Road, Panihati, Sodepur, Kolkata-700114; 
      India.
FAU - Roy, Susmita
AU  - Roy S
AD  - Division of Pharmacology and Toxicology, Guru Nanak Institute of Pharmaceutical 
      Science and Technology, 157/F, Nilgunj Road, Panihati, Sodepur, Kolkata-700114; 
      India.
FAU - Das, Debanjana
AU  - Das D
AD  - Department of Biotechnology, National Institute of Pharmaceutical Education and 
      Research, EPIP Campus, Hajipur, Bihar 844102, India.
FAU - Marturi, Venkatesh
AU  - Marturi V
AD  - Department of Pharmacology and Toxicology, National Institute of Pharmaceutical 
      Education and Research, EPIP Campus, Hajipur, Bihar 844102, India.
FAU - Mondal, Chaitali
AU  - Mondal C
AD  - TCG Life Sciences (Chembiotek) Pvt. Ltd., Sector V, Salt Lake Electronics 
      Complex, Kolkata, West Bengal 700091, India.
FAU - Patra, Susmita
AU  - Patra S
AD  - Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, 
      West Bengal, India.
FAU - Haldar, Pallab Kanti
AU  - Haldar PK
AD  - Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, 
      West Bengal, India.
FAU - Samajdar, Gourav
AU  - Samajdar G
AD  - Division of Pharmacology and Toxicology, Guru Nanak Institute of Pharmaceutical 
      Science and Technology, 157/F, Nilgunj Road, Panihati, Sodepur, Kolkata-700114; 
      India.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United Arab Emirates
TA  - Curr Diabetes Rev
JT  - Current diabetes reviews
JID - 101253260
RN  - 0 (Insulin)
RN  - EC 2.7.10.1 (Receptor, Insulin)
RN  - EC 2.7.11.26 (Glycogen Synthase Kinase 3)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/drug therapy/etiology/metabolism
MH  - Glycogen Synthase Kinase 3
MH  - Humans
MH  - Insulin/metabolism
MH  - *Insulin Resistance/physiology
MH  - Receptor, Insulin/metabolism
OTO - NOTNLM
OT  - Type 2 diabetes mellitus
OT  - etiology
OT  - glucose metabolism
OT  - glycogen synthase kinase-3
OT  - insulin sensitivity
OT  - modern targets
EDAT- 2021/08/12 06:00
MHDA- 2022/05/18 06:00
CRDT- 2021/08/11 05:31
PHST- 2020/11/12 00:00 [received]
PHST- 2021/02/15 00:00 [revised]
PHST- 2021/04/26 00:00 [accepted]
PHST- 2021/08/12 06:00 [pubmed]
PHST- 2022/05/18 06:00 [medline]
PHST- 2021/08/11 05:31 [entrez]
AID - CDR-EPUB-116973 [pii]
AID - 10.2174/1573399817666210730094225 [doi]
PST - ppublish
SO  - Curr Diabetes Rev. 2022;18(3):e300721195147. doi: 
      10.2174/1573399817666210730094225.